Tomohiko Harada
Gifu Pharmaceutical University(JP)Kanagawa Rehabilitation Hospital(JP)
Publications by Year
Research Areas
Nausea and vomiting management, Anesthesia and Pain Management, Cancer therapeutics and mechanisms, Lung Cancer Research Studies, Sympathectomy and Hyperhidrosis Treatments
Most-Cited Works
- → Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk(2016)83 cited
- → Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial(2016)56 cited
- → Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers(2011)40 cited
- → Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects(2016)35 cited
- → Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers(2009)34 cited
- → Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis(2017)32 cited
- → 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study(2020)11 cited
- → Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer(2023)6 cited
- → Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan(2009)5 cited
- [Evaluation of short-time premedication with d-chlorpheniramine maleate injection for paclitaxel-induced hypersensitivity reaction].(2008)